{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:41:59Z","timestamp":1790628119268,"version":"4.1.0"},"reference-count":229,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T00:00:00Z","timestamp":1738972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Biologic therapies have revolutionized the treatment of severe allergic diseases, including asthma, atopic dermatitis (AD), chronic spontaneous urticaria (CSU), chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic gastrointestinal diseases (EGIDs), and allergic rhinitis (AR). These molecularly targeted agents provide significant benefits for patients unresponsive to conventional treatments by addressing underlying immune mechanisms, particularly type 2 inflammation driven by cytokines such as IL-4, IL-5, and IL-13. Recent advancements include biologics targeting alarmins like thymic stromal lymphopoietin (TSLP) and IL-33, which may address both type 2 and non-type 2 inflammation, broadening their therapeutic scope. Despite their effectiveness, biologics remain expensive, posing socioeconomic challenges, and there are concerns regarding long-term safety and inter-individual variability in responses. Promising innovations such as bispecific antibodies and ultra-long-acting agents are under investigation, alongside digital health tools like remote biomarker monitoring and AI-driven decision support systems, which aim to enhance personalized care. However, disparities in access, particularly for underserved populations, underscore the need for policy reforms and affordable biosimilars. This review synthesizes recent findings and emerging trends, highlighting the evolving role of biologics in transforming allergic disease management and offering insights into future research directions.<\/jats:p>","DOI":"10.3390\/jcm14041079","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T03:39:47Z","timestamp":1739158787000},"page":"1079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives"],"prefix":"10.3390","volume":"14","author":[{"given":"Ewa","family":"Alska","sequence":"first","affiliation":[{"name":"Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4459-5293","authenticated-orcid":false,"given":"Dariusz","family":"\u0141aszczych","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2202-3222","authenticated-orcid":false,"given":"Katarzyna","family":"Napi\u00f3rkowska-Baran","sequence":"additional","affiliation":[{"name":"Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4374-5331","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Szymczak","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9295-9387","authenticated-orcid":false,"given":"Alicja","family":"Rajewska","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra Ewa","family":"Rubisz","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Romaniuk","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Wrzesie\u0144","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Mu\u0107ka","sequence":"additional","affiliation":[{"name":"Student Research Club of Clinical Immunology, Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-1386","authenticated-orcid":false,"given":"Zbigniew","family":"Bartuzi","sequence":"additional","affiliation":[{"name":"Department of Allergology, Clinical Immunology and Internal Diseases, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University Torun, 85-067 Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1111\/all.15807","article-title":"Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study","volume":"78","author":"Shin","year":"2023","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41392-023-01344-4","article-title":"Pathogenesis of allergic diseases and implications for therapeutic interventions","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14737167.2020.1819793","article-title":"Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy","volume":"20","author":"Dierick","year":"2020","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"04052","DOI":"10.7189\/jogh.12.04052","article-title":"Global, regional, and national prevalence of asthma in 2019: A systematic analysis and modelling study","volume":"12","author":"Song","year":"2022","journal-title":"J. Glob. Health"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/bjd\/ljad339","article-title":"Global epidemiology of atopic dermatitis: A comprehensive systematic analysis and modelling study","volume":"190","author":"Tian","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_6","first-page":"16611","article-title":"Recent guidelines addressing chronic rhinosinusitis with nasal polyps: Practical aspects","volume":"133","author":"Rank","year":"2023","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"682","DOI":"10.5114\/ada.2020.99365","article-title":"Recorded prevalence of nasal polyps increases with age","volume":"38","author":"Raciborski","year":"2020","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/all.14037","article-title":"Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis","volume":"75","author":"Fricke","year":"2020","journal-title":"Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.37349\/eaa.2024.00041","article-title":"Eosinophilic gastrointestinal diseases: Current perspectives on pathogenesis and management","volume":"2","author":"Papaiakovou","year":"2024","journal-title":"Explor. Asthma Allergy"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100824","DOI":"10.1016\/j.waojou.2023.100824","article-title":"Prevalence, severity, and risk factors of allergic rhinitis among schoolchildren in Saudi Arabia: A national cross-sectional study, 2019","volume":"16","author":"Alnahas","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/02770903.2016.1220011","article-title":"Asthma control and productivity loss in those with work-related asthma: A population-based study","volume":"54","author":"Wong","year":"2017","journal-title":"J. Asthma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/JAA.S327659","article-title":"Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics","volume":"14","author":"Axelsson","year":"2021","journal-title":"J. Asthma Allergy"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population","volume":"139","author":"Fuxench","year":"2019","journal-title":"J. Investig. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100843","DOI":"10.1016\/j.waojou.2023.100843","article-title":"Disease burden and predictors associated with non-response to antihistamine-based therapy in chronic spontaneous urticaria","volume":"16","author":"Soong","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2200943","DOI":"10.1183\/13993003.00943-2022","article-title":"Rhinitis phenotypes and multimorbidities in the general population: The CONSTANCES cohort","volume":"61","author":"Bousquet","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ram\u00edrez-Jim\u00e9nez, F., Pav\u00f3n-Romero, G.F., Vel\u00e1squez-Rodr\u00edguez, J.M., L\u00f3pez-Garza, M.I., Lazarini-Ruiz, J.F., Guti\u00e9rrez-Quiroz, K.V., and Teran, L.M. (2023). Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020270"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"210144","DOI":"10.1183\/20734735.0144-2021","article-title":"A pragmatic guide to choosing biologic therapies in severe asthma","volume":"17","author":"Kavanagh","year":"2022","journal-title":"Breathe"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Dubini, M., Benzecry, V., Rivolta, F., Sangalli, A., Marzano, A.V., Pravettoni, V., Tavecchio, S., and Ferrucci, S.M. (2023). Asthma improvement in patients treated with dupilumab for severe atopic dermatitis. Front. Allergy, 4.","DOI":"10.3389\/falgy.2023.1223657"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jaip.2020.11.034","article-title":"Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect","volume":"9","author":"Ratchataswan","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Kinoshita, Y., and Sanuki, T. (2023). Review of Non-Eosinophilic Esophagitis-Eosinophilic Gastrointestinal Disease (Non-EoE-EGID) and a Case Series of Twenty-Eight Affected Patients. Biomolecules, 13.","DOI":"10.3390\/biom13091417"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of Different Biologics for Treating Chronic Rhinosinusitis With Nasal Polyps: A Network Analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/all.14494","article-title":"Economic considerations on the usage of biologics in the allergy clinic","volume":"76","author":"Azzano","year":"2021","journal-title":"Allergy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.waojou.2022.100737","article-title":"Risks and safety of biologics: A practical guide for allergists","volume":"16","author":"Sitek","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2147\/JIR.S269297","article-title":"Utilizing Predictive Inflammatory Markers for Guiding the Use of Biologicals in Severe Asthma","volume":"15","author":"Runnstrom","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"ref_25","first-page":"PA448","article-title":"Predicting real-world response to mepolizumab in severe asthma using machine learning","volume":"64","author":"Usuba","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.jaci.2017.03.008","article-title":"Biosimilars and drug development in allergic and immunologic diseases","volume":"139","author":"Bonini","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jaci.2021.10.001","article-title":"Advances in asthma: New understandings of asthma\u2019s natural history, risk factors, underlying mechanisms, and clinical management","volume":"148","author":"Miller","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/CM9.0000000000001990","article-title":"Characteristics, phenotypes, mechanisms and management of severe asthma","volume":"135","author":"Chung","year":"2022","journal-title":"Chin. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40248-016-0073-0","article-title":"Asthma-related deaths","volume":"11","author":"Vitale","year":"2016","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/resp.14520","article-title":"Biologics for severe asthma-Which, when and why?","volume":"28","author":"Shah","year":"2023","journal-title":"Respirol. Carlton. Vic."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","article-title":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: Similarities, differences and misconceptions","volume":"129","author":"Oppenheimer","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"00309","DOI":"10.1183\/23120541.00309-2020","article-title":"Identification and treatment of T2-low asthma in the era of biologics","volume":"7","author":"Kyriakopoulos","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.coi.2020.10.002","article-title":"Mechanisms of non-type 2 asthma","volume":"66","author":"Hudey","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107327","DOI":"10.1016\/j.rmed.2023.107327","article-title":"Approach to non-type 2 asthma","volume":"216","author":"Adrish","year":"2023","journal-title":"Respir. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2300826","DOI":"10.1183\/13993003.00826-2023","article-title":"Advances in non-type 2 severe asthma: From molecular insights to novel treatment strategies","volume":"64","author":"Liu","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_37","unstructured":"GINA (2024, December 13). Difficult-to-Treat & Severe Asthma Guide. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2024\/11\/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Loureiro, C.C., Amaral, L., Ferreira, J.A., Lima, R., Pardal, C., Fernandes, I., Semedo, L., and Arrobas, A. (2018). Omalizumab for Severe Asthma: Beyond Allergic Asthma. BioMed Res. Int., 2018.","DOI":"10.1155\/2018\/3254094"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1080\/17476348.2020.1739526","article-title":"Benralizumab: An updated treatment of eosinophilic asthma","volume":"14","author":"Cushen","year":"2020","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Sardon-Prado, O., Diaz-Garcia, C., Corcuera-Elosegui, P., Korta-Murua, J., Valverde-Molina, J., and Sanchez-Solis, M. (2023). Severe Asthma and Biological Therapies: Now and the Future. J. Clin. Med., 12.","DOI":"10.3390\/jcm12185846"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2217\/imt-2019-0008","article-title":"Dupilumab in the Treatment of Asthma","volume":"11","author":"Grey","year":"2019","journal-title":"Immunotherapy"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2147\/JAA.S342391","article-title":"Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types","volume":"17","author":"Panettieri","year":"2024","journal-title":"J. Asthma. Allergy"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Wechsler, M.E., Jackson, D.J., Bernstein, D., Korn, S., Pfeffer, P.E., Chen, R., Saito, J., Martinez, G.d.L., Dymek, L., and Jacques, L. (2024). Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2406673"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.anai.2024.09.016","article-title":"Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma","volume":"134","author":"Seluk","year":"2024","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/13543784.2016.1227319","article-title":"Lebrikizumab for the treatment of asthma","volume":"25","author":"Antoniu","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Marone, G., Granata, F., Pucino, V., Pecoraro, A., Heffler, E., Loffredo, S., Scadding, G.W., and Varricchi, G. (2019). The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.01387"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/cea.13731","article-title":"A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER)","volume":"50","author":"Austin","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e12176","DOI":"10.1002\/clt2.12176","article-title":"Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)","volume":"12","author":"Szefler","year":"2022","journal-title":"Clin. Transl. Allergy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.jaip.2024.02.007","article-title":"Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population","volume":"12","author":"Corren","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"England, E., Rees, D.G., Scott, I.C., Carmen, S., Chan, D.T.Y., Huntington, C.E.C., Houslay, K.F., Erngren, T., Penney, M., and Majithiya, J.B. (2023). Tozorakimab (MEDI3506): An anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-36642-y"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ding, W., Zou, G.-L., Zhang, W., Lai, X.-N., Chen, H.-W., and Xiong, L.-X. (2018). Interleukin-33: Its Emerging Role in Allergic Diseases. Molecules, 23.","DOI":"10.3390\/molecules23071665"},{"key":"ref_54","first-page":"A65","article-title":"S90 FRONTIER-3: A randomized, phase 2a study to evaluate the efficacy and safety of tozorakimab (an anti-interleukin-33 monoclonal antibody) in early-onset asthma","volume":"79","author":"Corren","year":"2024","journal-title":"Thorax"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/cts.13157","article-title":"Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials","volume":"15","author":"Kosloski","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Akinseye, C., Crim, C., Newlands, A., and Fairman, D. (2023). Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0281205"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1111\/bcp.14361","article-title":"The first-in-human study of CNTO 7160, an anti-interleukin-33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis","volume":"86","author":"Nnane","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jacig.2022.07.002","article-title":"IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial","volume":"1","author":"Crim","year":"2022","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Bagnasco, D., Testino, E., Nicola, S., Melissari, L., Russo, M., Canevari, R.F., Brussino, L., and Passalacqua, G. (2022). Specific Therapy for T2 Asthma. J. Pers. Med., 12.","DOI":"10.3390\/jpm12040593"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaci.2021.03.044","article-title":"Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial","volume":"148","author":"Kelsen","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/resp.12299","article-title":"Mechanisms of pathogenesis in allergic asthma: Role of interleukin-23","volume":"19","author":"Li","year":"2014","journal-title":"Respirology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200801-086OC","article-title":"IL-23 and Th17 Cells Enhance Th2-Cell\u2013mediated Eosinophilic Airway Inflammation in Mice","volume":"178","author":"Wakashin","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2030880","article-title":"Risankizumab in Severe Asthma\u2014A Phase 2a, Placebo-Controlled Trial","volume":"385","author":"Brightling","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Garg, D., Que, L.G., and Ingram, J.L. (2024). Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1315540"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2201193","DOI":"10.1183\/13993003.01193-2022","article-title":"Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma","volume":"61","author":"Gauvreau","year":"2023","journal-title":"Eur. Respir. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1111\/cts.13112","article-title":"REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics","volume":"14","author":"Kamal","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jaci.2022.06.025","article-title":"REGN1908\/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit","volume":"150","author":"Gherasim","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"AB172","DOI":"10.1016\/j.jaci.2019.12.359","article-title":"Local Airway Concentration of Anti-Tryptase Antibody (MTPS9579A) Predicts Extent of Tryptase Disruption","volume":"145","author":"Rymut","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.molimm.2014.04.001","article-title":"Human mast cell tryptase in biology and medicine","volume":"63","author":"Vitte","year":"2015","journal-title":"Mol. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/cts.13163","article-title":"Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial","volume":"15","author":"Rymut","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/cts.13483","article-title":"A mechanistic PK\/PD model to enable dose selection of the potent anti-tryptase antibody (MTPS9579A) in patients with moderate-to-severe asthma","volume":"16","author":"Rymut","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1111\/all.16309","article-title":"Airway tryptase levels inform the lack of clinical efficacy of the tryptase inhibitor MTPS9579A in asthma","volume":"79","author":"Rhee","year":"2024","journal-title":"Allergy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in Adults with Uncontrolled Asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","volume":"384","author":"Corren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ricciardolo, F.L.M., Carriero, V., and Bertolini, F. (2021). Which Therapy for Non-Type(T)2\/T2-Low Asthma. J. Pers. Med., 12.","DOI":"10.3390\/jpm12010010"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaci.2014.07.039","article-title":"IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers","volume":"135","author":"Hernandez","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40259-024-00668-z","article-title":"Long-Term Efficacy and Safety of Stapokibart in Adults with Moderate-to-Severe Atopic Dermatitis: An Open-Label Extension, Nonrandomized Clinical Trial","volume":"38","author":"Zhao","year":"2024","journal-title":"BioDrugs"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"243ra85","DOI":"10.1126\/scitranslmed.3008961","article-title":"Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production","volume":"6","author":"Gauvreau","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_84","unstructured":"(2024, December 12). Solrikitug Phase II Clinical Trial|ATS 2024. Available online: https:\/\/www.delveinsight.com\/ats-conference\/ats-2024\/solrikitug-phase-ii-clinical-trial."},{"key":"ref_85","unstructured":"(2024, December 12). Innovent Announces First Participant Dosed in a Phase I Study of IBI3002 (an Anti-IL-4R\u03b1\/TSLP Bispecific Antibody) in Australia. Available online: https:\/\/pharmashots.com\/press-releases\/innovent-announces-first-participant-dosed-in-a-phase-i-study-of-ibi3002-an-anti-il-4r%CE%B1tslp-bispecific-antibody-in-australia."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e13864","DOI":"10.1111\/cts.13864","article-title":"A first-in-human, single and multiple dose study of lunsekimig, a novel anti-TSLP\/anti-IL-13 NANOBODY\u00ae compound, in healthy volunteers","volume":"17","author":"Deiteren","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"112189","DOI":"10.1016\/j.intimp.2024.112189","article-title":"Precision medicine for severe asthma\u2014Biological targeted therapy","volume":"134","author":"Sun","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"100274","DOI":"10.1016\/j.waojou.2020.100274","article-title":"IL-13-induced periostin production from human bronchial epithelial cells and human nasal epithelial cells","volume":"13","author":"Suzaki","year":"2020","journal-title":"World Allergy Organ. J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): Two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1802250","DOI":"10.1183\/13993003.02250-2018","article-title":"The interleukin-13 paradox in asthma: Effective biology, ineffective biologicals","volume":"53","author":"Nair","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e842","DOI":"10.1002\/iid3.842","article-title":"Elevated levels of interleukin-33 are associated with asthma: A meta-analysis","volume":"11","author":"Zhao","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Morikubo, H., Tojima, R., Maeda, T., Matsuoka, K., Matsuura, M., Miyoshi, J., Tamura, S., and Hisamatsu, T. (2024). Machine learning using clinical data at baseline predicts the medium-term efficacy of ustekinumab in patients with ulcerative colitis. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55126-1"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.aller.2018.12.002","article-title":"Prevalence of asthma, allergic rhinitis and eczema in 6-7-year-old schoolchildren from Luanda, Angola","volume":"47","author":"Arrais","year":"2019","journal-title":"Allergol. Immunopathol. (Madr)"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on Atopic Dermatitis: Diagnosis, Severity Assessment, and Treatment Selection","volume":"8","author":"Fishbein","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/DER.0000000000000895","article-title":"The Eczema Area and Severity Index\u2014A Practical Guide","volume":"33","author":"Hanifin","year":"2022","journal-title":"Dermatitis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","article-title":"Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies","volume":"90","author":"Davis","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_97","unstructured":"Dupilumab Label, FDA-Approved Drugs Database (2024, November 11). Drugs@FDA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761055s064lbl.pdf."},{"key":"ref_98","unstructured":"(2024, December 18). Tralokinumab Label, FDA-Approved Drugs Database, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761180s001lbl.pdf."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00403-024-03319-z","article-title":"Interleukin-1\u03b1 inhibitor bermekimab in patients with atopic dermatitis: Randomized and nonrandomized studies","volume":"316","author":"Simpson","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/bjd\/ljad022","article-title":"Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials","volume":"188","author":"Blauvelt","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/jamadermatol.2024.2192","article-title":"Systemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update","volume":"160","author":"Drucker","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamadermatol.2024.2131","article-title":"Cendakimab in Patients With Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial","volume":"160","author":"Blauvelt","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"AB194","DOI":"10.1016\/j.jaad.2024.07.773","article-title":"53652 Efficacy and safety of eblasakimab in adults with severe atopic dermatitis: A posthoc analysis of the Phase 2b TREK-AD trial","volume":"91","author":"Simpson","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jaci.2023.11.924","article-title":"Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)","volume":"153","author":"Silverberg","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"ljae266.086","DOI":"10.1093\/bjd\/ljae266.086","article-title":"712-Positive 52-week maintenance data observed with rademikibart in patients with moderate-to-severe atopic dermatitis (SEASIDE CHINA)","volume":"191","author":"Zhang","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"e13874","DOI":"10.1111\/cts.13874","article-title":"Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate-to-severe atopic dermatitis: Results from two terminated phase II trials","volume":"17","author":"Kosloski","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/jcph.2360","article-title":"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06817024 in Healthy Participants, Participants with Chronic Rhinosinusitis with Nasal Polyps, and Participants with Atopic Dermatitis: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study","volume":"64","author":"Danto","year":"2024","journal-title":"J. Clin. Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.jaci.2022.08.015","article-title":"Phase 2 randomized clinical trial of astegolimab in patients with moderate to severe atopic dermatitis","volume":"150","author":"Maurer","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Kabashima, K., and Irie, H. (2021). Interleukin-31 as a Clinical Target for Pruritus Treatment. Front. Med., 8.","DOI":"10.3389\/fmed.2021.638325"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): Results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Liang, J., Hu, F., Dan, M., Sang, Y., Abulikemu, K., Wang, Q., Hong, Y., and Kang, X. (2022). Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.825312"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1358\/dot.2022.58.4.3378056","article-title":"Nemolizumab for atopic dermatitis","volume":"58","author":"Labib","year":"2022","journal-title":"Drugs Today"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1111\/all.16346","article-title":"Targeting the IL-5 pathway in eosinophilic asthma: A comparison of anti-IL-5 versus anti-IL-5 receptor agents","volume":"79","author":"Jackson","year":"2024","journal-title":"Allergy"},{"key":"ref_114","first-page":"e1211","article-title":"Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial","volume":"37","author":"Bahadori","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol. JEADV."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.jid.2023.01.040","article-title":"IgE Depletion with Ligelizumab Does Not Significantly Improve Clinical Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis","volume":"143","author":"Bangert","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40257-023-00838-9","article-title":"OX40 in the Pathogenesis of Atopic Dermatitis\u2014A New Therapeutic Target","volume":"25","author":"Croft","year":"2024","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/bjd\/ljad240","article-title":"Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: Results of a phase IIa randomized placebo-controlled trial","volume":"189","author":"Weidinger","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","article-title":"An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: A multicentre, double-blind, placebo-controlled phase 2b study","volume":"401","author":"Simpson","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40259-023-00587-5","article-title":"Targeting IL-36 in Inflammatory Skin Diseases","volume":"37","author":"Fukaura","year":"2023","journal-title":"BioDrugs"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/jdv.18727","article-title":"Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: Results from a multicentre, randomized, double-blind, placebo-controlled, phase IIa study","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"111706","DOI":"10.1016\/j.intimp.2024.111706","article-title":"Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study","volume":"130","author":"Ye","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"82","DOI":"10.5414\/ALX02194E","article-title":"Turning off the alarm\u2014Targeting alarmins and other epithelial mediators of allergic inflammation with biologics","volume":"5","author":"Albrecht","year":"2021","journal-title":"Allergologie"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.jaad.2018.11.059","article-title":"Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial","volume":"80","author":"Simpson","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1016\/j.jaip.2024.08.054","article-title":"Factors Associated With Dupilumab Response in Atopic Dermatitis: A Systematic Review and Meta-Analysis","volume":"12","author":"Chokevittaya","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/bjd\/ljad032","article-title":"Serum biomarker-based endotypes of atopic dermatitis in China and prediction for efficacy of dupilumab","volume":"188","author":"Wu","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti\u2013IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/all.15647","article-title":"IL-13, periostin and dipeptidyl-peptidase-4 reveal endotype-phenotype associations in atopic dermatitis","volume":"78","author":"Maintz","year":"2023","journal-title":"Allergy"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s13555-021-00678-7","article-title":"Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents","volume":"12","author":"Sidbury","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"adv00433","DOI":"10.2340\/00015555-3796","article-title":"Global Epidemiology of Urticaria: Increasing Burden among Children, Females and Low-income Regions","volume":"101","author":"Peck","year":"2021","journal-title":"Acta Dermato-Venereologica"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"22799036241243268","DOI":"10.1177\/22799036241243268","article-title":"Does chronic urticaria affect quality of sleep and quality of life?","volume":"13","author":"Awad","year":"2024","journal-title":"J. Public Health Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/bjd.14768","article-title":"Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: A systematic review and meta-analysis","volume":"175","author":"Presa","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e13749","DOI":"10.1111\/srt.13749","article-title":"Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta-analysis","volume":"30","author":"Xu","year":"2024","journal-title":"Ski. Res. Technol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamadermatol.2018.3447","article-title":"Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of \u201cReal-world\u201d Evidence","volume":"155","author":"Tharp","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/all.14547","article-title":"Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2500\/aap.2024.45.230092","article-title":"Total IgE as a biomarker of omalizumab response in chronic spontaneous urticaria: A meta-analysis","volume":"45","author":"Keller","year":"2024","journal-title":"Allergy Asthma Proc."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1358\/dot.2017.53.9.2693150","article-title":"Dupilumab: Human monoclonal antibody against IL-4R\u03b1 for moderate to severe atopic dermatitis","volume":"53","author":"Paton","year":"2017","journal-title":"Drugs Today"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s13555-024-01231-y","article-title":"Dupilumab Reduces Urticaria Activity, Itch, and Hives in Patients with Chronic Spontaneous Urticaria Regardless of Baseline Serum Immunoglobulin E Levels","volume":"14","author":"Maurer","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_141","unstructured":"Benralizumab Label, FDA-Approved Drugs Database (2024, November 11). Drugs@FDA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761070s021lbl.pdf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/bjd\/ljae067","article-title":"Benralizumab does not elicit therapeutic effect in patients with chronic spontaneous urticaria: Results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial","volume":"191","author":"Altrichter","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1038\/s41467-022-33176-1","article-title":"Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy","volume":"13","author":"An","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41467-019-13815-w","article-title":"The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab","volume":"11","author":"Gasser","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for Chronic Spontaneous Urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0140-6736(23)01684-7","article-title":"Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: Results of two phase 3 randomised controlled trials","volume":"403","author":"Ensina","year":"2024","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00228-024-03725-2","article-title":"Time-course and dose-effect of omalizumab in treating chronic idiopathic urticaria\/chronic spontaneous urticaria","volume":"80","author":"Zhao","year":"2024","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"e157765","DOI":"10.1172\/JCI157765","article-title":"IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms","volume":"132","author":"Kuo","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/mabs.4.1.18349","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects","volume":"4","author":"Zhou","year":"2012","journal-title":"mAbs"},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Youngblood, B.A., Leung, J., Falahati, R., Williams, J., Schanin, J., Brock, E.C., Singh, B., Chang, A.T., O\u2019sullivan, J.A., and Schleimer, R.P. (2020). Discovery, Function, and Therapeutic Targeting of Siglec-8. Cells, 10.","DOI":"10.3390\/cells10010019"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/j.jaci.2021.12.772","article-title":"An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria","volume":"149","author":"Altrichter","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_152","unstructured":"Canakinumab Label, FDA-Approved Drugs Database (2024, November 11). Drugs@FDA, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125319s110lbl.pdf."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jaip.2020.07.058","article-title":"Canakinumab Lacks Efficacy in Treating Adult Patients with Moderate to Severe Chronic Spontaneous Urticaria in a Phase II Randomized Double-Blind Placebo-Controlled Single-Center Study","volume":"9","author":"Maul","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_154","first-page":"522","article-title":"Eosinophilic Gastrointestinal Diseases Beyond the Esophagus: An Evolving Field and Nomenclature","volume":"18","author":"Redd","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.cgh.2022.02.017","article-title":"International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/MPG.0000000000003877","article-title":"Joint ESPGHAN\/NASPGHAN Guidelines on Childhood Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis","volume":"78","author":"Papadopoulou","year":"2024","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jaci.2021.12.768","article-title":"Impressions and aspirations from the FDA GREAT VI Workshop on Eosinophilic Gastrointestinal Disorders Beyond Eosinophilic Esophagitis and Perspectives for Progress in the Field","volume":"149","author":"Rothenberg","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Marasco, G., Visaggi, P., Vassallo, M., Fiocca, M., Cremon, C., Barbaro, M.R., De Bortoli, N., Bellini, M., Stanghellini, V., and Savarino, E.V. (2023). Current and Novel Therapies for Eosinophilic Gastrointestinal Diseases. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015165"},{"key":"ref_159","first-page":"49","article-title":"Omalizumab in the management of patients with allergic (IgE-mediated) asthma","volume":"2","year":"2009","journal-title":"J. Asthma Allergy"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"60","DOI":"10.37349\/eaa.2023.00009","article-title":"Eosinophilic gastrointestinal disorders: New perspectives and the emerging role of biological therapies","volume":"1","author":"Losa","year":"2023","journal-title":"Explor. Asthma Allergy"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.anai.2018.06.013","article-title":"Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis","volume":"121","author":"Egan","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13223-024-00878-8","article-title":"Eosinophilic gastritis and gluten-sensitive enteropathy manifested as hypoproteinemia and treated with omalizumab: A case report","volume":"20","author":"Du","year":"2024","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"118973","DOI":"10.1016\/j.lfs.2020.118973","article-title":"Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities","volume":"267","author":"Lee","year":"2021","journal-title":"Life Sci."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S0091-6749(03)80986-7","article-title":"Pilot study of anti-IL-5 in eosinophilic gastroenteritis","volume":"111","author":"Prussin","year":"2003","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti\u2013IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"100676","DOI":"10.1016\/j.waojou.2022.100676","article-title":"Current and emerging biologic therapies targeting eosinophilic disorders","volume":"15","author":"Pitlick","year":"2022","journal-title":"World Allergy Organ. J."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2147\/JAA.S258594","article-title":"Anti-IL5 Therapies for Severe Eosinophilic Asthma: Literature Review and Practical Insights","volume":"13","author":"Menzella","year":"2020","journal-title":"J. Asthma Allergy"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","article-title":"Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome","volume":"380","author":"Kuang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(23)00145-0","article-title":"Benralizumab for eosinophilic gastritis: A single-site, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"8","author":"Kliewer","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"S2648","DOI":"10.14309\/01.ajg.0000966380.17521.88","article-title":"S4185 Beyond the Esophagus: Dupilumab\u2019s Potential in Treatment of Eosinophilic Gastritis","volume":"118","author":"Thomas","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e00646","DOI":"10.14309\/ctg.0000000000000646","article-title":"Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series","volume":"15","author":"Sia","year":"2024","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.2169\/internalmedicine.0801-22","article-title":"Successful Treatment of Steroid-resistant Eosinophilic Gastrointestinal Disease with Mepolizumab","volume":"62","author":"Ito","year":"2023","journal-title":"Intern. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000512805","article-title":"Vedolizumab in Inflammatory Bowel Disease: West versus East","volume":"6","author":"Debnath","year":"2021","journal-title":"Inflamm. Intest. Dis."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s10620-019-05617-3","article-title":"Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab","volume":"64","author":"Grandinetti","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"449","DOI":"10.51821\/86.3.11869","article-title":"Non-esophageal eosinophilic gastrointestinal diseases: A narrative review","volume":"86","author":"Janssens","year":"2023","journal-title":"Acta Gastro Enterol. Belg."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.cgh.2018.03.024","article-title":"Vedolizumab Treatment May Reduce Steroid Burden and Improve Histology in Patients With Eosinophilic Gastroenteritis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.anai.2019.12.001","article-title":"Biologics in chronic rhinosinusitis with nasal polyposis","volume":"124","author":"Laidlaw","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaip.2016.04.012","article-title":"Chronic Rhinosinusitis with Nasal Polyps","volume":"4","author":"Stevens","year":"2016","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.jaip.2022.01.016","article-title":"Epidemiology of Chronic Rhinosinusitis: Prevalence and Risk Factors","volume":"10","author":"Sedaghat","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE Guidelines for the Medical Management of Chronic Rhinosinusitis with Nasal Polyposis","volume":"151","author":"Rank","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_182","first-page":"85","article-title":"The EUFOREA pocket guide for chronic rhinosinusitis","volume":"61","author":"Hellings","year":"2022","journal-title":"Rhinology"},{"key":"ref_183","unstructured":"Masson, E. (2024, November 26). Comparative Efficacy and Safety of Monoclonal Antibodies and Aspirin Desensitization for Chronic Rhinosinusitis with Nasal Polyposis: A Systematic Review and Network Meta-Analysis. Available online: https:\/\/www.em-consulte.com\/article\/1509938\/comparative-efficacy-and-safety-of-monoclonal-anti."},{"key":"ref_184","first-page":"194","article-title":"EPOS\/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023","volume":"61","author":"Fokkens","year":"2023","journal-title":"Rhinology"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/1744666X.2023.2231150","article-title":"Dupilumab in chronic rhinosinusitis with nasal polyposis: Current status, challenges, and future perspectives","volume":"19","author":"Li","year":"2023","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1111\/all.15772","article-title":"Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL)","volume":"78","author":"Pasquini","year":"2023","journal-title":"Allergy"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jaip.2021.12.006","article-title":"Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies","volume":"10","author":"Geng","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/alr.23234","article-title":"Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents\u2019 efficacy","volume":"14","author":"Papacharalampous","year":"2024","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1177\/19458924221112211","article-title":"Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design","volume":"36","author":"Peters","year":"2022","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jaci.2019.05.019","article-title":"Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort","volume":"145","author":"Namazy","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5414\/ALX02460E","article-title":"Monitoring mepolizumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP): Discontinue, change, continue therapy?","volume":"8","author":"Klimek","year":"2024","journal-title":"Allergol. Sel."},{"key":"ref_193","first-page":"320","article-title":"Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE","volume":"62","author":"Mullol","year":"2024","journal-title":"Rhinology"},{"key":"ref_194","first-page":"576","article-title":"Mepolizumab in CRSwNP\/ECRS and NP: The phase III randomised MERIT trial in Japan, China, and Russia","volume":"62","author":"Fujieda","year":"2024","journal-title":"Rhinology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1016\/j.jaip.2023.08.015","article-title":"Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps","volume":"11","author":"Chupp","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/all.15434","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): In-depth sinus surgery analysis","volume":"78","author":"Fokkens","year":"2023","journal-title":"Allergy"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/alr.23219","article-title":"Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up","volume":"14","author":"Desrosiers","year":"2024","journal-title":"Int. Forum Allergy Rhinol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1111\/bcp.16087","article-title":"Pharmacokinetics\/pharmacodynamics of benralizumab in chronic rhinosinusitis with nasal polyps: Phase III, randomized, placebo-controlled OSTRO trial","volume":"90","author":"Emson","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and Safety of Benralizumab in Chronic Rhinosinusitis with Nasal Polyps: A Randomized, Placebo-controlled Trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am. J. Rhinol. Allergy"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"749","DOI":"10.2147\/JAA.S275039","article-title":"Targeting TSLP in Asthma","volume":"15","author":"Parnes","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"e00904-17","DOI":"10.1128\/AAC.00904-17","article-title":"A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections","volume":"61","author":"Xiong","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e0065524","DOI":"10.1128\/aac.00655-24","article-title":"Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip","volume":"68","author":"Conway","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12968\/hmed.2021.0570","article-title":"Allergic rhinitis: Diagnosis and management","volume":"83","author":"Siddiqui","year":"2022","journal-title":"Br. J. Hosp. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4168\/aair.2023.15.1.19","article-title":"KAAACI Allergic Rhinitis Guidelines: Part 1. Update in Pharmacotherapy","volume":"15","author":"Yang","year":"2023","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_207","first-page":"e68607","article-title":"Recent Advances in Allergic Rhinitis: A Narrative Review","volume":"16","author":"Tidke","year":"2024","journal-title":"Cureus"},{"key":"ref_208","first-page":"501","article-title":"Omalizumab for the treatment of allergic rhinitis: A systematic review and meta-analysis","volume":"59","author":"Tsabouri","year":"2021","journal-title":"Rhinology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2500\/aap.2023.44.230015","article-title":"Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis","volume":"44","author":"Peters","year":"2023","journal-title":"Allergy Asthma Proc."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2022.08.029","article-title":"Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial","volume":"151","author":"Corren","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1164\/rccm.202011-4107OC","article-title":"Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial","volume":"204","author":"Shamji","year":"2021","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.eclinm.2024.102467","article-title":"Efficacy and safety of stapokibart (CM310) in uncontrolled seasonal allergic rhinitis (MERAK): An investigator-initiated, placebo-controlled, randomised, double-blind, phase 2 trial","volume":"69","author":"Zhang","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jaci.2021.05.038","article-title":"Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response","volume":"149","author":"Atanasio","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13555-023-01058-z","article-title":"Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis","volume":"14","author":"Rand","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_215","unstructured":"Katoh, N., Tsunemi, Y., Kamata, M., Dossenbach, M., and Hanada, T. (2023, January 11\u201314). An indirect comparison of lebrikizumab, dupilumab, and tralokinumab in Japanese patients with moderate to severe atopic dermatitis by network meta-analysis methodology. Proceedings of the European Academy of Dermatology and Venerology Congress, Berlin, Germany. Available online: https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.eadv\/abstracts_congress2023\/37622.pdf."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"110721","DOI":"10.1016\/j.isci.2024.110721","article-title":"Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2024.07.1447","article-title":"Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial","volume":"91","author":"Zhao","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/cts.13656","article-title":"Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4R\u03b1: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis","volume":"16","author":"Wang","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"00448-2024","DOI":"10.1183\/23120541.00448-2024","article-title":"IL1RL1variant may affect the response to type 2 biologics in patients with severe asthma","volume":"11","author":"Nishi","year":"2024","journal-title":"ERJ Open Res."},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Porsbjerg, C.M., Townend, J., Bergeron, C., Christoff, G.C., Katsoulotos, G.P., Larenas-Linnemann, D., Tran, T.N., Al-Lehebi, R., Bosnic-Anticevich, S.Z., and Busby, J. (2024). Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1361891"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Thomas, V.A., and Balthasar, J.P. (2019). Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies, 8.","DOI":"10.3390\/antib8040056"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"ljae266.041","DOI":"10.1093\/bjd\/ljae266.041","article-title":"667-Maintenance of efficacy and safety with nemolizumab at week 48: Results from two global phase 3 pivotal studies (ARCADIA-1 and ARCADIA-2) in patients with moderate-to-severe atopic dermatitis","volume":"191","author":"Silverberg","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Boada-Fern\u00e1ndez-Del-Campo, C., Garc\u00eda-S\u00e1nchez-Colomer, M., Fern\u00e1ndez-Quintana, E., Poza-Guedes, P., Rolingson-Landaeta, J.L., S\u00e1nchez-Mach\u00edn, I., and Gonz\u00e1lez-P\u00e9rez, R. (2024). Real-World Safety Profile of Biologic Drugs for Severe Uncontrolled Asthma: A Descriptive Analysis from the Spanish Pharmacovigilance Database. J. Clin. Med., 13.","DOI":"10.20944\/preprints202404.1515.v1"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s13555-024-01135-x","article-title":"Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus","volume":"14","author":"Gargiulo","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12931-021-01758-0","article-title":"Real-life cost-effectiveness of benralizumab in patients with severe asthma","volume":"22","author":"Abitbol","year":"2021","journal-title":"Respir. Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1080\/13696998.2023.2234235","article-title":"Cost-effectiveness of tezepelumab in Canada for severe asthma","volume":"26","author":"Habash","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1080\/13696998.2023.2209417","article-title":"Real-world patient-level cost-effectiveness analysis of omalizumab in patients with severe allergic asthma treated in four major medical centers in Turkey","volume":"26","author":"Tugay","year":"2023","journal-title":"J. Med. Econ."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","article-title":"Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?","volume":"122","author":"Anderson","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1111\/all.15740","article-title":"Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach\u2014ARIA-EAACI Task Force Report","volume":"78","author":"Bousquet","year":"2023","journal-title":"Allergy"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:29:17Z","timestamp":1760027357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,8]]},"references-count":229,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041079"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041079","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,8]]}}}